Join Us in Solving Pandemic-Sized Problems

Investor Overview

Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company was founded to help stop the current coronavirus pandemic (COVID-19) and prevent the next. Pardes scientists developed a novel oral antiviral treatment for COVID-19, pomotrelvir, from concept through phase 2 testing in under three years. In addition, our research efforts have generated highly potent new chemical entities with broad spectrum pan-coronavirus activity to help better prepare for future threats. Our lead program, pomotrelvir, our research assets, and intellectual property are available for partnering while the company explores a range of strategic alternatives. Contact us here.

Learn More

Stock
Quote

Volume:

09/11/2023 5:04 PMEDT

Press
Releases

08/31/2023

Pardes Biosciences Announces Closing of Tender Offer

07/17/2023

Pardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value Rights

05/05/2023

Pardes Biosciences Reports First Quarter 2023 Financial Results

04/03/2023

Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19

Webcasts

Financial Information

Document Date	Description	Form	View
12/21/2021	Filing of certain prospectuses and communications in connection with business combination transactions	425	View HTML 0001213900-21-066517.pdf 0001213900-21-066517.rtf
12/21/2021	Filing of certain prospectuses and communications in connection with business combination transactions	425	View HTML 0001213900-21-066643.pdf 0001213900-21-066643.rtf
12/22/2021	Statement of changes in beneficial ownership of securities	4	View HTML 0001213900-21-067341.pdf 0001213900-21-067341.rtf 0001213900-21-067341.xls
12/23/2021	Report of unscheduled material events or corporate event	8-K	View HTML 0001213900-21-067218.pdf 0001213900-21-067218.rtf 0001213900-21-067218.xls EX-101.LAB - XBRL LABEL FILE
12/23/2021	Filing of certain prospectuses and communications in connection with business combination transactions	425	View HTML 0001213900-21-067222.pdf 0001213900-21-067222.rtf 0001213900-21-067222.xls
12/23/2021	Report of unscheduled material events or corporate event	8-K	View HTML 0001213900-21-067249.pdf 0001213900-21-067249.rtf 0001213900-21-067249.xls EX-101.DEF - XBRL DEFINITION FILE
12/23/2021	Amendment to a previously filed 8-A12B	8-A12B/A	View HTML 0001213900-21-067252.pdf 0001213900-21-067252.rtf 0001213900-21-067252.xls
12/23/2021	Report of unscheduled material events or corporate event	8-K	View HTML 0001193125-21-366671.pdf 0001193125-21-366671.rtf EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
12/23/2021	Initial filing by director officer or owner of more than ten percent.	3	View HTML 0000899243-21-049782.pdf 0000899243-21-049782.rtf 0000899243-21-049782.xls
12/23/2021	Initial filing by director officer or owner of more than ten percent.	3	View HTML 0000899243-21-049784.pdf 0000899243-21-049784.rtf 0000899243-21-049784.xls

Contact
IR

Send us an investor-related question using the form below.